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Abstract 23 
Treatments for Clostridium difficile infection remain limited, despite the introduction 24 
of fidaxomicin, and development of new agents is necessary.  25 
We determined the in vitro susceptibilities of 199 prevalent or emerging Clostridium 26 
difficile PCR ribotypes to MCB3681, a novel investigational quinolonyl-oxazolidinone, 27 
and 8 comparators (metronidazole, vancomycin, fidaxomicin, moxifloxacin, 28 
ciprofloxacin, clindamycin, tigecycline and linezolid). 29 
MCB3681 showed good activity against C. difficile with no evidence of MCB3681 30 
resistance in isolates showing either or both moxifloxacin and linezolid resistance.  31 
 32 
C. difficile infection (CDI) is a major burden on healthcare resources. CDI is thought 33 
to arise following the depletion of gut microflora by antimicrobial action, allowing the 34 
organism to proliferate and cause disease. Antimicrobial treatments for CDI are 35 
currently limited to metronidazole, vancomycin and fidaxomicin. Metronidazole has 36 
more recently been associated with treatment failures, while promotion of 37 
glycopeptide resistance within the host microflora is a risk associated with 38 
vancomycin therapy. 1 Symptomatic recurrence is common following treatment with 39 
these agents, 2 requiring further episodes of antimicrobial therapy. Further treatment 40 
options are highly desirable to broaden the range of therapeutic choice and 41 
strengthen antimicrobial stewardship.  42 
MCB3681 is a novel small molecule with structural elements of an oxazolidinone and 43 
a quinolone showing good activity against C. difficile, including isolates that were 44 
resistant to linezolid, ciprofloxacin, moxifloxacin and clindamycin. 3 It achieves high 45 
faecal concentrations after intravenous infusions and has shown activity against 46 
Gram positive components of the gut microflora in a clinical Phase 1 study 4. The 47 
development of an intravenous treatment agent achieving high faecal concentrations 48 
would circumvent issues of rapid gut transit, or impaired delivery of orally 49 
administered agents due to ileus, particularly in patients with severe or 50 
protracted/multiple recurrent diarrhoeal episodes. 51 
We determined the in vitro activities of MCB3681 and 8 comparators (metronidazole, 52 
vancomycin, moxifloxacin, ciprofloxacin, clindamycin, tigecycline, linezolid, and 53 
fidaxomicin) against a panel of 200 Clostridium difficile isolates of known PCR 54 
ribotypes (RT) from 21 European countries (selected from the ClosER study - July 55 
2011-April 2013, by kind permission of Astellas Pharma Europe). 5  56 
 57 
In vitro susceptibility testing was performed using a Wilkins-Chalgren agar 58 
incorporation method, as previously described.5,7 Briefly, C. difficile test isolates and 59 
control strains (C. difficile ATCC 750057, C. difficile E4 PCR ribotype 010, 60 
Bacteroides fragilis ATCC 25285, Enterococcus faecalis ATCC 29212 and 61 
Staphlyococcus aureus ATCC 29213 were cultured anaerobically at 37oC for 24h in 62 
Schaedler’s anaerobic broths prior to dilution to 0.5 McFarland standard 63 
equivalence) in pre-reduced sterile saline and inoculation onto antibiotic-containing 64 
and control Wilkins-Chalgren agar plates. Inoculated plates were incubated 65 
anaerobically at 37oC for 48h.  66 
 67 
MCB3681 is a quinolonyl- oxazolidinone antibacterial which has previously 68 
demonstrated good activity against C. difficile. 3 All the CDI treatment agents, 69 
including MCB3681 showed good activity against the isolates tested (Table 1). 70 
Fidaxomicin was the most active treatment agent (Kruskal-Wallis p<0.0001; 71 
geometric mean (GM) MIC=0.05 mg/L), followed by MCB3681 (p<0.0001; GM=0.12 72 
mg/L), then metronidazole (p<0.0001; GM=0.33 mg/L), with no evidence of 73 
resistance to any of these compounds (Table 1). Vancomycin was the least active 74 
(p<0.0001; GM=1.02 mg/L), but resistance was very scarce (1.5%; 75 
breakpoint>8mg/L). Reduced metronidazole susceptibility (4 mg/L) was observed in 76 
only 1% of isolates. GM metronidazole MICs were elevated in RT027 (0.96 mg/L) 77 
and RT106 (0.74 mg/L) vs GM metronidazole MICs for all isolates tested (0.33 78 
mg/L), in agreement with previous data.4  79 
 80 
All isolates were resistant to ciprofloxacin according to the breakpoints defined 81 
(Table 1), and 48% of isolates showed moxifloxacin resistance, including at least one 82 
isolate in each RT group tested. Highly elevated MICs to both moxifloxacin (>32 83 
mg/L) and ciprofloxacin (>128 mg/L) were prevalent in RT001, RT027 and RT356. 84 
Clindamycin MICs were highest in RT001, RT017 and RT126 (GM MICs = 61.11 85 
mg/L; 64 mg/L and 38.05 mg/L, respectively), but there was evidence of clindamycin 86 
resistance in all RTs tested (Table 1). There was no evidence of tigecycline 87 
resistance (range=0.03-0.125mg/L; GM=0.05mg/L), in agreement with previous data 88 
(Table 1).4 The majority of isolates (78.9%) were sensitive to linezolid (Table 1), with 89 
a GM MIC of 5.16 mg/L. RT001 and RT017 showed the highest GM linezolid MICs 90 
(10.08 mg/L and 7.03 mg/L, respectively). This is also in agreement with previous 91 
observations.7 Three RT017, and two RT027 isolates showed dual quinolone-92 
oxzolidinone resistant phenotype, and showed MCB3681 MICs of 0.5 mg/L. We 93 
have previously reported that these isolates showed high level resistance to 94 
chloramphenicol (Table 2).5,8 Marin et al. reported linezolid, chloramphenicol, 95 
erythromycin, and clindamycin resistance associated with the presence of the 96 
multidrug resistance gene, cfr, in C. difficile RT017, RT078 and RT126 isolates.11 97 
The MIC50 and MIC90 values reported here for MCB3681 are similar to those recently 98 
described for cadazolid, another quinolonyl-oxazolidinone molecule.9 A previous 99 
study investigating susceptibility of C. difficile to cadazolid and comparators, reported 100 
an association between resistance to either moxifloxacin or linezolid and 101 
moxifloxacin/linezolid double-resistant mutants, and 2- or 4-fold higher cadazolid 102 
MICs in mono- or double-resistant isolates, respectively. 10 However, the highest 103 
MCB3681 MIC was 0.5 mg/L, and we also found isolates with moxifloxacin, 104 
ciprofloxacin, linezolid and chloramphenicol resistance that demonstrated very low 105 
MCB3681 MICs (0.008 mg/L) (Table 2). We did not investigate the molecular basis 106 
of resistance in these isolates, but the results do not suggest a link between this 107 
phenotype and MCB3681 MICs. The results shown here, in conjunction with those 108 
previously reported8, 11 would also indicate that other modes of resistance to linezolid 109 
(23s rRNA alterations, ribosomal protein modifications) may be at play in 110 
combination with quinolone resistance mechanisms. 111 
 112 
Rashid et al. reported MICs of MCB3681 for C. difficile ranged from 0.008-0.5 mg/L,3 113 
which were similar to our results (range 0.008-0.5 mg/L). However, in the present 114 
study, MIC50 and MIC90 values were 0.125 and 0.25 mg/L, respectively, which were 115 
marginally higher than those reported previously, but within 2 doubling dilutions (0.03 116 
and 0.06 mg/L, respectively). This may be explained by methodological/agar or C. 117 
difficile strain distribution differences. The influence of testing media and 118 
components therein on MICs has previously been reported and may have been a 119 
factor in the differences observed.7,12 We used a Wilkins-Chalgren agar incorporation 120 
method to determine MICs, since is superior to CLSI-recommended Brucella blood 121 
agar (BBA) in the detection of reduced susceptibility to metronidazole in C. difficile.7  122 
 123 
This study builds on this previous data of Rashid et al by substantially expanding the 124 
diversity of ribotypes examined to include, in particular, RT027 and  several RTs 125 
already noted for resistance to multiple antimicrobials: RT001, RT017, RT018, 126 
RT027 and RT356.,5,8 There was no evidence of MCB3681 resistance among them. 127 
MCB3681 achieves faecal concentrations of 99-226mg/kg after intravenous 128 
infusions, far in excess of MIC ranges for C. difficile reported here. MCB3681 has 129 
been reported to be active against Gram-positive gut microflora bacteria, but sparing 130 
of Gram-negative organisms in human volunteer studies with intravenous 131 
administration over 5 days. Further data are needed to assess the impact of 132 
MCB3681 on C. difficile and the gut microflora over a longer duration.  133 
 134 
In summary, MCB3681 showed good activity against C. difficile isolates from 135 
emerging or prevalent European PCR ribotypes with no evidence of resistance. The 136 
presence of quinolone and/or linezolid resistance did not influence MCB3681 MICs. 137 
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mg/L MCB3681 FDX MTZ VAN MXF CIP CLI TGC LZD 
Breakpoints 
S<4;  
 
R>42 
S <1;  
 
RS >14 
S<2; 
I=4; 
R>84 
S<2; 
I=4; 
R>84 
S<2; 
I=4; 
R>84 
S <8;  
 
RS >82 
S<2;  
I=4;  
R>84 
S<4;  
 
RS>44 
S<4;  
 
R>47 
%S 100 100 99 96 50.5 - 5.5 100 78.9 
%I - - 1 2.5 1 - 29.5 - - 
%R  -  - 0 1.5 48 100 54 - 21.1 
MIC50 0.125 0.06 0.25 1 2 64 16 0.06 4 
MIC90 0.25 0.125 1 2 32 256 128 0.06 8 
range 0.008-0.5 
0.004-
0.25 
<0.125-
4 0.5-8 
1-
>64 8->128 1->64 0.03-0.125 2->64 
Geometric mean 
MIC (mg/L) 
 
RT001 (15) 0.07 0.02 0.42 0.79 16.00 111.43 61.11 0.03 10.08 
RT002 (14) 0.11 0.06 0.19 0.87 1.82 27.86 12.13 0.04 4.39 
RT005 (16) 0.14 0.06 0.29 1.16 2.00 37.12 9.28 0.04 5.66 
RT014 (16) 0.11 0.07 0.28 0.88 3.36 39.74 10.37 0.05 4.36 
RT015 (15) 0.14 0.06 0.25 0.87 1.91 26.60 7.29 0.04 4.19 
RT017 (16) 0.15 0.04 0.26 0.74 12.88 86.67 64.00 0.06 7.03 
RT018 (14) 0.12 0.06 0.41 1.49 6.90 110.33 8.83 0.04 4.42 
RT020 (15) 0.10 0.06 0.25 0.75 2.59 36.44 11.31 0.05 4.76 
RT027 (16) 0.16 0.09 0.96 1.14 21.67 206.14 19.87 0.05 5.19 
RT078 (16) 0.11 0.05 0.26 0.92 2.38 34.90 12.34 0.05 5.42 
RT106 (14) 0.11 0.09 0.74 1.10 7.61 81.98 10.77 0.04 4.42 
RT126 (16) 0.12 0.06 0.32 1.00 8.35 72.88 38.05 0.06 4.56 
RT356 (16) 0.08 0.04 0.27 2.28 29.34 245.15 12.88 0.04 4.76 
All isolates (199) 0.12 0.05 0.33 1.02 5.87 66.27 16.17 0.05 5.16 
Table 1. Susceptibility of 199 C. difficile isolates to MCB3681 and 8 comparators.  
FDX= fidaxomicin; MTZ=metronidazole, VAN= vancomcyin; MXF=moxifloxacin;CIP=ciprofloxacin; CLI=clindamycin; TGC=tigecycline; LZD=linezolid 
S=sensitive; I=intermediate; R=resistant; RS=reduced susceptibility 
 
 
 
 MIC (mg/L) 
RT MXF CIP LZD CLI CHL MCB3681 
001 16 128 32 >64 32 0.008 
001 32 128 32 >64 32 0.015 
001 32 128 32 >64 32 0.015 
001 16 64 16 >64 8 0.25 
001 16 >128 32 >64 8 0.25 
001 16 >128 32 >64 32 0.25 
001 16 >128 32 >64 32 0.25 
014 16 >128 32 16 16 0.06 
017 32 128 64 >64 2 0.06 
017 16 64 16 >64 32 0.25 
017 32 64 16 >64 64 0.5 
017 32 64 32 >64 >64 0.5 
017 32 128 32 >64 64 0.5 
018 16 >128 8 8 4 0.03 
018 32 >128 8 8 2 0.06 
027 32 >128 32 >64 64 0.5 
027 32 >128 32 >64 64 0.5 
078 8 128 8 4 4 0.125 
078 16 >128 8 4 64 0.125 
106 16 128 8 8 4 0.06 
126 16 64 16 >64 4 0.125 
356 32 >128 8 8 4 0.03 
356 32 >128 8 8 8 0.06 
356 32 >128 8 8 4 0.25 
356 >64 128 8 16 4 0.25 
Table 2 MCB3681 MICs (mg/L) in C. difficile isolates with dual quinolone-oxazolidinone resistance (highlighting indicates resistance). Clindamycin and 
chloramphenicol MICs4 are also shown. 
MXF=moxifloxacin; CIP=ciprofloxacin; LZD=linezolid; CLI=clindamycin; CHL=chloramphenicol 
